Association between Ophthalmic Timolol and Hospitalisation for Bradycardia
Introduction. Ophthalmic timolol, a topical nonselective beta-blocker, has the potential to be absorbed systemically which may cause adverse cardiovascular effects. This study was conducted to determine whether initiation of ophthalmic timolol was associated with an increased risk of hospitalisation...
Saved in:
Main Authors: | Nicole L. Pratt, Emmae N. Ramsay, Lisa M. Kalisch Ellett, Tuan A. Nguyen, Elizabeth E. Roughead |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2015-01-01
|
Series: | Journal of Ophthalmology |
Online Access: | http://dx.doi.org/10.1155/2015/567387 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Development and Evaluation of Polymethacrylate-Based Ophthalmic Nanofiber Inserts Containing Dual Drug-Loaded Dorzolamide and Timolol: In Vivo Study in Rabbit’s Eye
by: Ahmad Karami, et al.
Published: (2025-01-01) -
Sugammadex-Associated Hypotension, Bradycardia, Asystole, and Death
by: Kazim Mirza, et al.
Published: (2020-01-01) -
Maternal Bradycardia Associated with Betamethasone Administration During Pregnancy
by: Mojirayo A. Sarumi, et al.
Published: (2019-01-01) -
Topical Timolol as a Therapeutic Modality in Severe Disfiguring Infantile Haemangioma
by: Mohita Mahajan, et al.
Published: (2024-01-01) -
Syncope vs. Seizure: Ictal Bradycardia and Ictal Asystole
by: Sumika Ouchida, et al.
Published: (2024-01-01)